Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
DraftKings Inc. stock logo
DKNG
DraftKings
$18.42
-2.5%
$20.88
$16.55
▼
$36.98
$9.53B1.6517.84 million shs10.50 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$215.27
-3.6%
$203.06
$22.28
▼
$280.80
$93.61B1.1615.52 million shs7.00 million shs
10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
DraftKings Inc. stock logo
DKNG
DraftKings
0.00%+2.05%-0.05%-25.34%-36.14%
Moderna, Inc. stock logo
MRNA
Moderna
0.00%-12.12%+2.46%+246.52%+801.78%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
DraftKings Inc. stock logo
DKNG
DraftKings
$18.42
-2.5%
$20.88
$16.55
▼
$36.98
$9.53B1.6517.84 million shs10.50 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$215.27
-3.6%
$203.06
$22.28
▼
$280.80
$93.61B1.1615.52 million shs7.00 million shs
10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
DraftKings Inc. stock logo
DKNG
DraftKings
0.00%+2.05%-0.05%-25.34%-36.14%
Moderna, Inc. stock logo
MRNA
Moderna
0.00%-12.12%+2.46%+246.52%+801.78%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
DraftKings Inc. stock logo
DKNG
DraftKings
2.64
Moderate Buy$27.6149.91% Upside
Moderna, Inc. stock logo
MRNA
Moderna
2.08
Hold$113.75-47.16% Downside

Current Analyst Ratings Breakdown

Latest MRNA and DKNG Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/11/2026
DraftKings Inc. stock logo
DKNG
DraftKings
UpgradeStrong Sell ➝ Hold
11/10/2026
DraftKings Inc. stock logo
DKNG
DraftKings
DowngradeBuy ➝ Hold$27.50 ➝ $20.00
11/10/2026
DraftKings Inc. stock logo
DKNG
DraftKings
Lower Price TargetBuy$28.00 ➝ $22.00
11/9/2026
DraftKings Inc. stock logo
DKNG
DraftKings
Lower Price TargetBuy$30.00 ➝ $28.00
11/9/2026
Moderna, Inc. stock logo
MRNA
Moderna
Reiterated RatingOverweight$230.00 ➝ $305.00
11/9/2026
DraftKings Inc. stock logo
DKNG
DraftKings
Reiterated RatingPositive$23.00
11/9/2026
DraftKings Inc. stock logo
DKNG
DraftKings
Lower Price TargetOutperform$45.00 ➝ $35.00
11/9/2026
DraftKings Inc. stock logo
DKNG
DraftKings
Lower Price TargetBuy$30.00 ➝ $25.00
11/9/2026
DraftKings Inc. stock logo
DKNG
DraftKings
Reiterated RatingBuy$28.00
11/9/2026
DraftKings Inc. stock logo
DKNG
DraftKings
DowngradeBuy ➝ Hold$32.00 ➝ $21.00
11/9/2026
DraftKings Inc. stock logo
DKNG
DraftKings
DowngradeBuy ➝ Neutral$48.00 ➝ $22.00
(Data available from 11/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
DraftKings Inc. stock logo
DKNG
DraftKings
$6.05B1.52$0.71 per share25.77$0.36 per share51.17
Moderna, Inc. stock logo
MRNA
Moderna
$1.94B44.81N/AN/A$16.90 per share12.74
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
DraftKings Inc. stock logo
DKNG
DraftKings
$3.71M-$0.80N/A15.742.51-5.91%-43.92%-4.92%N/A
Moderna, Inc. stock logo
MRNA
Moderna
-$2.82B-$7.10N/AN/AN/A-110.46%-25.79%-15.85%N/A

Latest MRNA and DKNG Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/6/2026Q3 2026
Moderna, Inc. stock logo
MRNA
Moderna
-$1.10$0.38+$1.48$0.38$890.25 million$1.31 billion
11/5/2026Q3 2026
DraftKings Inc. stock logo
DKNG
DraftKings
-$0.4102-$0.53-$0.1198-$0.94$1.39 billion$1.33 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
DraftKings Inc. stock logo
DKNG
DraftKings
N/AN/AN/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
DraftKings Inc. stock logo
DKNG
DraftKings
12.21
0.99
1.02
Moderna, Inc. stock logo
MRNA
Moderna
0.52
3.62
3.47

Institutional Ownership

CompanyInstitutional Ownership
DraftKings Inc. stock logo
DKNG
DraftKings
37.70%
Moderna, Inc. stock logo
MRNA
Moderna
75.33%

Insider Ownership

CompanyInsider Ownership
DraftKings Inc. stock logo
DKNG
DraftKings
47.18%
Moderna, Inc. stock logo
MRNA
Moderna
10.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
DraftKings Inc. stock logo
DKNG
DraftKings
5,500498.29 million263.20 millionOptionable
Moderna, Inc. stock logo
MRNA
Moderna
4,700404.62 million360.92 millionOptionable

Recent News About These Companies

Top Biotech Stocks To Consider - November 16th
Top Biotech Stocks To Add to Your Watchlist - November 15th
Aberdeen Group plc Buys 1,039,311 Shares of Moderna, Inc. $MRNA
Moderna, Inc. (MRNA) - What Are Analysts Saying About This Stock?
The Single Most Important Metric For Moderna Stock
Moderna (NASDAQ:MRNA) Stock Price Down 3.4% - Time to Sell?
Moderna, Inc. (MRNA) Analyst/Investor Day - Slideshow
Moderna Issues Cost Outlook Amid Revenue Uncertainty, Stock Falls
Promising Biotech Stocks To Consider - November 13th
Brookline Capital Markets Forecasts Moderna FY2026 Earnings

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
DraftKings stock logo

DraftKings NASDAQ:DKNG

$18.42 -0.47 (-2.49%)
Closing price 04:00 PM Eastern
Extended Trading
$18.34 -0.08 (-0.43%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

DraftKings Inc. operates as a digital sports entertainment and gaming company in the United States and internationally. It provides online sports betting and casino, daily fantasy sports, media, and other consumer products, as well as retails sportsbooks. The company also engages in the design and development of sports betting and casino gaming software for online and retail sportsbooks, and iGaming operators. In addition, it offers DraftKings marketplace, a digital collectibles ecosystem designed for mainstream accessibility that offers curated NFT drops and supports secondary-market transactions. The company is headquartered in Boston, Massachusetts.

Moderna stock logo

Moderna NASDAQ:MRNA

$215.27 -8.10 (-3.63%)
Closing price 04:00 PM Eastern
Extended Trading
$213.50 -1.77 (-0.82%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.